Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary central nervous system lymphoma.

Igor T Gavrilovic1, Lauren E Abrey

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Current Oncology Reports
|August 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment.

Neuro-oncology practice·2026
Same author

Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas.

JCO precision oncology·2026
Same author

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.

Neuro-oncology·2026
Same author

Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.

Acta neuropathologica·2025
Same author

Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.

Neuro-oncology·2025
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Primary central nervous system lymphoma (PCNSL) treatment combines methotrexate chemotherapy and radiotherapy, improving outcomes but risking neurotoxicity. Future strategies aim to reduce radiotherapy by intensifying chemotherapy or using biologic therapies.

Area of Science:

  • Oncology
  • Neurology
  • Hematology

Background:

  • Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin's lymphoma with increasing incidence.
  • Methotrexate chemotherapy combined with whole-brain radiotherapy (WBRT) has improved PCNSL patient outcomes.
  • Treatment-related neurotoxicity, particularly in the elderly, is a significant complication of WBRT.

Purpose of the Study:

  • To address critical questions regarding optimal methotrexate dosing and adjunct therapies for PCNSL.
  • To explore strategies for limiting radiotherapy use and mitigating associated neurotoxicity.
  • To investigate the potential of oncogenic proteins as prognostic markers for risk-adapted PCNSL therapies.

Main Methods:

  • Review of current treatment protocols for PCNSL.

Related Experiment Videos

  • Analysis of treatment-related neurotoxicity data, especially in elderly patients.
  • Exploration of emerging biologic therapies and chemotherapy intensification strategies.

    • Main Results:

    • Methotrexate-based chemotherapy and WBRT are standard, yet neurotoxicity remains a concern.
    • Optimal methotrexate dose, frequency, and adjunct chemotherapy regimens require further investigation.
    • Biologic therapies and intensified chemotherapy show promise in reducing reliance on radiotherapy.

    Conclusions:

    • Further research is needed to optimize PCNSL treatment protocols, balancing efficacy with reduced neurotoxicity.
    • Biologic therapies and advanced chemotherapy delivery strategies may offer alternatives to WBRT.
    • Identifying prognostic markers could enable personalized, risk-adapted treatment approaches for PCNSL.